Reviewer's report

Title: Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report

Version: 4 Date: 12 June 2015

Reviewer: Seth Furgeson

Reviewer's report:

Discretionary Revisions

Based on the case report, there is a plausible connection between rhabdomyolysis and abiraterone/denosumab therapy. As the authors acknowledge, there is not enough data to confirm causality but the time course and lack of alternative explanation supports their conclusions. The statin therapy is a confounding problem. Although rosuvastatin is not metabolized by CYP3A4, levels may be affected by inhibition of hepatic organic anion transporter. Does either drug inhibit OATP1b1?

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.